INS and Hypoglycemia: There was a substantially lower risk (HR 0.18, 95% CI 0.08–0.49) of incident hypoglycaemia with IDegLira versus ICT in our real-world study, which was somewhat lower than the estimated risk ratio of 0.39 (95% CI 0.29–0.51) for IDegLira versus basal–bolus insulin reported in DUAL VII [17].